Carregant...
The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study
INTRODUCTION: We evaluated the predictive factors which affect the efficacy of naftopidil 50 mg/day therapy and dose increase therapy to administration of 75 mg/day after an initial dose of 50 mg/day. MATERIALS AND METHODS: A total of 92 patients with male lower urinary tract symptoms/benign prostat...
Guardat en:
| Publicat a: | Urol Ann |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Medknow Publications & Media Pvt Ltd
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5532895/ https://ncbi.nlm.nih.gov/pubmed/28794594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/UA.UA_23_17 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|